Asia Pacific Seasonal Influenza Vaccine Market: Cell Culture Technology Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity

2011-12-16
Published : Dec-2011

Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity

Summary

GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Description” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2017. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines.  The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.

Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 8.9% during the period 2010-2017 from $1,154.9m in 2010 to $2,095.9m by 2017. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies.

GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2010-2017. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.

GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.

Scope

- Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
- Market forecasts for the seasonal influenza vaccines from 2010 to 2017
- Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
- Key drivers and restraints that have created significant impact on the market.
- Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
- Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
- Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the seasonal influenza vaccine market.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 11
2 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Introduction 14
2.1 GBI Research Report Guidance 15
3 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Market Overview 16
3.1 Production Cycle for the Seasonal Influenza Vaccines 16
3.2 The Asia-Pacific Region Seasonal Influenza Vaccine Market 16
3.3 Revenue for the Seasonal Influenza Vaccine Market 17
3.4 Geographical Segmentation 19
4 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Geographical Landscape 20
4.1 Australia 20
4.1.1 Vaccination Pattern 20
4.1.2 Cost of Vaccine 25
4.1.3 Total Revenue 26
4.2 New Zealand 28
4.2.1 Vaccination Pattern 28
4.2.2 Cost of Vaccine 33
4.2.3 Total Revenue 34
4.2.4 Major Players by Market Share 36
4.3 Taiwan 37
4.3.1 Vaccination Pattern 37
4.3.2 Cost of Vaccine 41
4.3.3 Total Revenue 42
4.3.4 Major Players by Market Share 44
4.4 Philippines 45
4.4.1 Vaccination Pattern 45
4.4.2 Cost of Vaccine 49
4.4.3 Total Revenue 50
4.4.4 Major Players by Market Share 52
4.5 Malaysia 53
4.5.1 Vaccination Pattern 53
4.5.2 Cost of Vaccine 57
4.5.3 Total Revenue 58
4.5.4 Major Players by Market Share 60
4.6 Hong Kong 61
4.6.1 Vaccination Pattern 61
4.6.2 Cost of Vaccine 65
4.6.3 Total Revenue 66
4.6.4 Major Players by Market Share 68
4.7 Singapore 69
4.7.1 Vaccination Pattern 69
4.7.2 Cost of Vaccine 73
4.7.3 Total Revenue 74
4.7.4 Major Players by Market Share 76
4.8 Japan 77
4.8.1 Vaccination Pattern 77
4.8.2 Cost of Vaccine 81
4.8.3 Total Revenue 82
4.8.4 Major Players in the Market 83
4.9 China 84
4.9.1 Vaccination Pattern 84
4.9.2 Cost of Vaccine 88
4.9.3 Total Revenue 89
4.9.4 Major Players in the Market 91
4.10 India 92
4.10.1 Vaccination Pattern 92
4.10.2 Cost of Vaccine 96
4.10.3 Total Revenue 97
4.10.4 Major Players in the Market 99
5 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Drivers and Restraints 100
5.1 Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 100
5.1.1 Threat of Pandemic Influenza 100
5.1.2 Increasing Vaccination Coverage for Seasonal Influenza Vaccines 101
5.1.3 Emergence of Novel Production Technologies and Vaccines 104
5.1.4 Population Growth 105
5.1.5 Economic Reasons 105
5.2 Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 105
5.2.1 Entry Barriers in the Seasonal Influenza Vaccine Market 105
5.2.2 Variable Demand 106
5.2.3 Limited Production Capacity 106
5.3 Australia 106
5.3.1 Drivers 106
5.3.2 Restraints 106
5.4 New Zealand 107
5.4.1 Drivers 107
5.4.2 Restraints 107
5.5 Taiwan 107
5.5.1 Drivers 107
5.5.2 Restraints 107
5.6 Philippines 108
5.6.1 Drivers 108
5.6.2 Restraints 108
5.7 Malaysia 108
5.7.1 Drivers 108
5.7.2 Restraints 108
5.8 Hong Kong 109
5.8.1 Drivers 109
5.8.2 Restraints 109
5.9 Singapore 109
5.9.1 Drivers 109
5.9.2 Restraints 110
5.10 Japan 110
5.10.1 Drivers 110
5.10.2 Restraints 110
5.11 China 111
5.11.1 Drivers 111
5.11.2 Restraints 111
5.12 India 111
5.12.1 Drivers 111
5.12.2 Restraints 111
6 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Regulatory Landscape 112
6.1 Registration Process and Regulations in Australia 112
6.2 Registration Process and Regulations in New Zealand 114
6.3 Registration Process and Regulations in Taiwan 117
6.4 Registration Process and Regulations in the Philippines 118
6.5 Registration Process and Regulations in Malaysia 120
6.6 Registration Process and Regulations in Hong Kong 122
6.7 Registration Process and Regulations in Singapore 123
6.8 Registration Process and Regulations in Japan 124
6.9 Registration Process and Regulations in China 126
6.10 Registration Process and Regulations in India 128
7 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Pipeline Analysis 130
7.1 Seasonal Influenza Vaccines – Promising Vaccines under Clinical Development 130
7.2 Profiles for Promising Vaccines under Clinical Development 131
7.2.1 Optaflu 131
7.2.2 GSK2186877A 131
7.2.3 Intanza / Flu-ID 132
7.2.4 Fluad Pediatric 133
7.2.5 FluBlok 133
7.3 Research and Development Pipeline 134
8 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Competitive Landscape 138
8.1 Major Seasonal Influenza Vaccines Marketed in the APAC Region 138
8.1.1 Fluarix 138
8.1.2 Vaxigrip 138
8.1.3 Influvac 138
8.1.4 Fluvax 138
8.1.5 Agrippal 138
8.2 Key Areas Focused for R&D 139
8.3 Competitive Profiling 140
8.3.1 Sanofi Pasteur 140
8.3.2 GlaxoSmithKline Biologicals 140
8.3.3 Abbott Laboratories (Solvay Pharmaceuticals) 140
8.3.4 CSL Biotherapies 140
8.3.5 Novartis Vaccines 141
8.3.6 Crucell N.V. (Berna Biotech) 141
9 Seasonal Influenza Vaccine Market in Asia-Pacific Region – M&A Landscape 142
9.1 Overview 142
9.2 Major Merger and Acquisition Deals, 2007-2011 142
9.2.1 AstraZeneca Acquires Medimmune 143
9.2.2 Sanofi-Aventis (now Sanofi) Acquires Acambis 143
9.2.3 Mymetics Acquires Virosome Biologicals 143
9.2.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock 143
9.2.5 Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan 144
9.2.6 Abbott Laboratories Acquires Solvay Pharmaceuticals 144
9.2.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno 144
9.2.8 Johnson & Johnson Acquires Crucell 144
9.2.9 GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals 144
9.3 M&A Deals by Year of Completion, 2007-2011 145
9.4 M&A Deals by Geography 146
9.5 Major Licensing Agreements, 2007-2011 146
9.5.1 Crucell enters into License Agreement with Adimmune Corporation 146
9.5.2 MedImmune Enters into Licensing Agreement with Sanofi Pasteur 147
9.5.3 Vivalis enters into Licensing Agreement with GlaxoSmithKline 147
9.5.4 Vivalis enters into Licensing Agreement with Nobilon International 147
9.5.5 MedImmune enters into Licensing Agreement with GlaxoSmithKline 147
9.5.6 Hemispherx Biopharma Enters Into Licensing Agreement with BIKEN 147
9.5.7 MedImmune Enters Into Licensing Agreement with BIKEN 147
9.5.8 MedImmune Enters Into Licensing Agreement with Omninvest 148
9.5.9 OPKO Health Enters Into Licensing Agreement with Academia Sinica 148
9.5.10 AltraVax Enters Into Licensing Agreement with Maxygen 148
9.5.11 Protein Sciences Expands Its Licensing Agreement with UMN Pharma for FluBlok and PanBlok 148
9.5.12 NasVax Extends Its Research Agreement with Novartis 148
9.5.13 iBio Enters Into Licensing Agreement With G-Con 148
9.6 Licensing Deals by Year of Completion, 2007-2011 149
9.7 Licensing Deals by Geography 150
10 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Appendix 151
10.1 Market Definitions 151
10.2 Abbreviations 151
10.3 Research Methodology 152
10.3.1 Coverage 152
10.3.2 The Scope of the Study 152
10.3.3 Secondary Research 153
10.3.4 Primary Research 153
10.3.5 Expert Panel Validation 155
10.4 Contact Us 156
10.5 Disclaimer 156
10.6 Sources 156

1.1 List of Tables
Table 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue, ($m), 2010-2017 17
Table 2: Seasonal Influenza Vaccine Market, Australia, Population (‘000), 2010-2017 20
Table 3: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Contribution by Age Groups (%), 2010-2017 21
Table 4: Seasonal Influenza Vaccine Market, Australia, Overall Vaccination Coverage (‘000), 2010 – 2017 23
Table 5: Seasonal Influenza Vaccine Market, Australia, Vaccination Coverage Break-up by Age Groups (‘000), 2010-2017 23
Table 6: Seasonal Influenza Vaccine Market, Australia, Overall Number of Doses (‘000), 2010-2017 23
Table 7: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Age Groups, (‘000), 2010-2017 24
Table 8: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Purchase Sector, (‘000), 2010-2017 25
Table 9: Seasonal Influenza Vaccine Market, Australia, Cost of Vaccine,($), 2010-2017 25
Table 10: Seasonal Influenza Vaccine Market, Australia, Revenue, ($m), 2010-2017 26
Table 11: Seasonal Influenza Vaccine Market, Australia, Revenue Breakdown, ($m), 2010-2017 27
Table 12: Seasonal Influenza Vaccine Market, New Zealand, Population (‘000), 2010-2017 28
Table 13: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution (%), 2010-2017 29
Table 14: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution by Age Groups (%), 2010-2017 29
Table 15: Seasonal Influenza Vaccine Market, New Zealand, Overall Vaccination Coverage (‘000), 2010-2017 31
Table 16: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Coverage by Age Groups (‘000), 2010-2017 31
Table 17: Seasonal Influenza Vaccine Market, New Zealand, Overall Number of Doses (‘000), 2010-2017 31
Table 18: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Age Groups (‘000), 2010-2017 32
Table 19: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Sector Contribution (‘000), 2010-2017 33
Table 20: Seasonal Influenza Vaccine Market, New Zealand Cost of Vaccine, ($), 2010-2017 33
Table 21: Seasonal Influenza Vaccine Market, New Zealand, Revenue, ($m), 2010-2017 34
Table 22: Seasonal Influenza Vaccine Market, New Zealand, Revenue Breakdown, ($m), 2010-2017 35
Table 23: Seasonal Influenza Vaccine Market, Taiwan, Population (‘000), 2010-2017 37
Table 24: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Contribution by Age Groups (%), 2010-2017 38
Table 25: Seasonal Influenza Vaccine Market, Taiwan, Overall Vaccination Coverage (‘000), 2010-2017 39
Table 26: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Coverage by Age Groups (‘000), 2010-2017 39
Table 27: Seasonal Influenza Vaccine Market, Taiwan, Overall Number of Doses (‘000), 2010-2017 39
Table 28: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Age Groups (‘000), 2010-2017 40
Table 29: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Sector Contribution (‘000), 2010-2017 41
Table 30: Seasonal Influenza Vaccine Market, Taiwan, Cost of Vaccine, ($), 2010-2017 41
Table 31: Seasonal Influenza Vaccine Market, Taiwan, Revenue, ($m), 2010-2017 42
Table 32: Seasonal Influenza Vaccine Market, Taiwan, Revenue Breakdown, ($m),  2010-2017 43
Table 33: Seasonal Influenza Vaccine Market, Philippines, Population (‘000), 2010-2017 45
Table 34: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Contribution by Age Groups (%), 2010-2017 46
Table 35: Seasonal Influenza Vaccine Market, Philippines, Overall Vaccination Coverage (‘000), 2010-2017 47
Table 36: Seasonal Influenza Vaccine Market, Philippines, Vaccination Coverage by Age Groups (‘000), 2010-2017 47
Table 37: Seasonal Influenza Vaccine Market, Philippines, Overall Number of Doses (‘000), 2010-2017 47
Table 38: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Age Groups (‘000), 2010-2017 48
Table 39: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Sector Contribution (‘000), 2010-2017 49
Table 40: Seasonal Influenza Vaccine Market, Philippines, Cost of Vaccine, ($), 2010-2017 49
Table 41: Seasonal Influenza Vaccine Market, Philippines, Revenue, ($m), 2010-2017 50
Table 42: Seasonal Influenza Vaccine Market, Philippines, Revenue Breakdown, ($m), 2010-2017 51
Table 43: Seasonal Influenza Vaccine Market, Malaysia, Population (‘000), 2010-2017 53
Table 44: Seasonal Influenza Vaccine Market, Malaysia, Overall Vaccinated Population Contribution (%), 2010-2017 54
Table 45: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Contribution by Age Groups (%), 2010-2017 54
Table 46: Seasonal Influenza Vaccine Market, Malaysia, Overall Vaccination Coverage (‘000), 2010-2017 55
Table 47: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Coverage by Age Groups (‘000), 2010-2017 55
Table 48: Seasonal Influenza Vaccine Market, Malaysia, Overall Number of Doses (‘000), 2010-2017 55
Table 49: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Age Groups (‘000), 2010-2017 56
Table 50: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Sector Contribution (‘000), 2010-2017 57
Table 51: Seasonal Influenza Vaccine Market, Malaysia, Cost of Vaccine, ($), 2010-2017 57
Table 52: Seasonal Influenza Vaccine Market, Malaysia, Revenue, ($m), 2010-2017 58
Table 53: Seasonal Influenza Vaccine Market, Malaysia, Revenue Breakdown, ($m),  2010-2017 59
Table 54: Seasonal Influenza Vaccine Market, Hong Kong, Population (‘000), 2010-2017 61
Table 55: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Contribution by Age Groups (%), 2010-2017 62
Table 56: Seasonal Influenza Vaccine Market, Hong Kong, Overall Vaccination Coverage (‘000), 2010-2017 63
Table 57: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Coverage by Age Groups (‘000), 2010-2017 63
Table 58: Seasonal Influenza Vaccine Market, Hong Kong, Overall Number of Doses (‘000), 2010-2017 63
Table 59: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Age Groups (‘000), 2010-2017 64
Table 60: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Sector Contribution (‘000), 2010-2017 65
Table 61: Seasonal Influenza Vaccine Market, Hong Kong, Cost of Vaccine, ($), 2010-2017 65
Table 62: Seasonal Influenza Vaccine Market, Hong Kong, Revenue, ($m), 2010-2017 66
Table 63: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Breakdown, ($m), 2010-2017 67
Table 64: Seasonal Influenza Vaccine Market, Singapore, Population (‘000), 2010-2017 69
Table 65: Seasonal Influenza Vaccine Market, Singapore, Overall Vaccinated Population Contribution (%), 2010-2017 70
Table 66: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Contribution by Age Groups (%), 2010-2017 70
Table 67: Seasonal Influenza Vaccine Market, Singapore, Overall Vaccination Coverage (‘000), 2010-2017 71
Table 68: Seasonal Influenza Vaccine Market, Singapore, Vaccination Coverage by Age Groups (‘000), 2010-2017 71
Table 69: Seasonal Influenza Vaccine Market, Singapore, Overall Number of Doses (‘000), 2010-2017 71
Table 70: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Age Groups (‘000), 2010-2017 72
Table 71: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Sector Contribution (‘000), 2010-2017 73
Table 72: Seasonal Influenza Vaccine Market, Singapore, Cost of Vaccine, ($), 2010-2017 73
Table 73: Seasonal Influenza Vaccine Market, Singapore, Revenue, ($m), 2010-2017 74

Filed in: Pharmaceutical
More Reports
Title Price Buy Now

EpiCast Report: Alzheimer’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026 Summary Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide. To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Sta......
$3995

EpiCast Report: Epilepsy – Epidemiology Forecast to 2026

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026 Summary Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain (WHO, 2017). It is one of the most common neurological conditions globally (WHO, 2017). Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered a seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis (NHS, 2014). In the 7MM, the lifetime diagnosed prevalent cases of epilepsy will increase from almost 11 million cases in 2016 to just over 11.5 million cases in 2026, at an Annual Growth Rate (AGR) of almost 0.5% pe......
$3995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Argentina

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina Summary Pharmaceutical market increased from over US$3 Billion in 2009 to around US$6.5 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of nearly 10%. It is expected to cross US$10 Billion in 2021 at a CAGR of about 10%. In 2009, the medical device market was valued at just over US$1 Billion. It grew at a CAGR of 4% between 2009 and 2016 and reached around US$1.3 Billion. It is expected to grow at a CAGR of about 5%, from around US$1.4 Billion in 2017 to over US$1.7 Billion in 2021. Argentina is the third-largest pharmaceutical market in Latin America after Brazil and Mexico. With a relatively low-cost base and high-quality professionals in the biotechnology sector, Argentina is home to over 130 ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report p......
$1000

EpiCast Report: Melanoma – Epidemiology Forecast to 2026

EpiCast Report: Melanoma - Epidemiology Forecast to 2026 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013). In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagn......
$3995

EpiCast Report: Crohn’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026 Summary Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon). The disease course of CD is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of the parts of the bowel. Our epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 a......
$3995

Hyperkalemia Global Clinical Trials Review, H2, 2017

Hyperkalemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperkalemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperkalemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperkalemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Hyperalgesia Global Clinical Trials Review, H2, 2017

Hyperalgesia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperalgesia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperalgesia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperalgesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Hyperlipidemia Global Clinical Trials Review, H2, 2017

Hyperlipidemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperlipidemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperlipidemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperlipidemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Hyperammonemia Global Clinical Trials Review, H2, 2017

Hyperammonemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperammonemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperammonemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperammonemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500